Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.

This article summarized the latest R&D progress of Flunisolide, the Mechanism of Action for Flunisolide, and the drug target R&D trends for Flunisolide.

Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.

This article summarized the latest R&D progress of Fenofibric acid, the Mechanism of Action for Fenofibric acid, and the drug target R&D trends for Fenofibric acid.

Two patients have been administered the initial dosage of SMART101, an allogeneic cell therapy created from donor mobilized peripheral blood stem cells which have been converted into T-cell progenitors utilizing the ProTcell treatment platform by Smart Immune.

This article summarized the latest R&D progress of Eletriptan hydrobromide, the Mechanism of Action for Eletriptan hydrobromide, and the drug target R&D trends for Eletriptan hydrobromide.

miRNA is an endogenous tiny non-coding RNA, generally 21-23 nucleotides long, with the function of regulating gene expression at the translational level.

This article summarized the latest R&D progress of Efavirenz, the Mechanism of Action for Efavirenz, and the drug target R&D trends for Efavirenz.

Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.

This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.

The Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is the only confirmed oncogenic protein.

This article summarized the latest R&D progress of Diflunisal, the Mechanism of Action for Diflunisal, and the drug target R&D trends for Diflunisal.